Angle PLC - Parsortix for Neuroendocrine Analysis in SCLC
For immediate release
4 September 2019
MEDICAL UNIVERSITY OF
Neuroendocrine markers on CTCs associated with poor overall survival
Potential for faster diagnosis, patient stratification and on-treatment therapy monitoring in lung cancer
This has been published as a peer-reviewed publication in the journal Cells and is available at https://angleplc.com/library/publications/.
The work for the first time investigates neuroendocrine markers on circulating tumor cells (CTCs) harvested by the Parsortix system. These were found to correlate with patients' poor overall survival. The investigation utilised RNA analysis on the CTCs, which cannot be achieved by analysis of ctDNA (fragments of dead cells).
SCLC is a highly aggressive neuroendocrine tumor of the lung and most patients present with metastatic disease at initial diagnosis. Utilising a Parsortix liquid biopsy based on a simple blood test could have numerous advantages compared to current standard of care including:
· fast and accurate diagnosis of SCLC, which can be challenging due to difficulties accessing the site and/or insufficient biopsied tissue;
· repeat liquid biopsies to guide treatment as the cancer evolves, which is not feasible with tissue biopsies due to the invasive injury to the patient, risks of medical complication and the high costs of tissue biopsy in lung cancer;
· determination by RNA analysis of the CTCs of suitable drugs and whether new targeted lung cancer drugs are likely to be effective for the patient.
Professor Robert Zeillinger, Head of the
"In this study we have demonstrated new approaches utilising ANGLE's Parsortix system to assess neuroendocrine markers in lung cancer. These markers correlate to the aggressiveness of the cancer and have the potential to significantly improve the way that lung cancer is diagnosed and treated."
ANGLE Founder and Chief Executive,
"Lung cancer is a major opportunity for ANGLE to pursue once we have concluded our current FDA and verification studies in breast cancer and ovarian cancer. We are encouraged by the work of
For further information ANGLE:
| || |
+44 (0) 1483 343434
finnCap Ltd (NOMAD and Joint Broker)
Corporate Finance -
+44 (0)20 7220 0500
+44 (0) 203 705 9330
+44 (0) 203 727 1000
+1 (212) 850 5624
For Frequently Used Terms, please see the Company's website on http://www.angleplc.com/the-parsortix-system/glossary/
Notes for editors
ANGLE is a world leading liquid biopsy company with sample-to-answer solutions. ANGLE's proven patent protected platforms include an epitope-independent circulating tumor cell (CTC) harvesting technology and a downstream analysis system for cost effective, highly multiplexed analysis of nucleic acids and proteins.
ANGLE's cell separation technology is called the Parsortix® system, and it enables a liquid biopsy (a simple blood test) to be used to provide the cells of interest to the user in a format suitable for multiple downstream subsequent analyses. CTCs enable the complete picture of a cancer to be seen as they allow DNA, RNA and protein analysis and the live cells harvested can be cultured. The Parsortix technology is the subject of 24 granted patents in
ANGLE's technology for the multiplex evaluation of proteins and nucleic acids of all types is called the HyCEADTM Ziplex® platform and is based on a patented flow through array technology. It provides for low cost, highly multiplexed, rapid and sensitive capture of targets from a wide variety of sample types. A proprietary chemistry approach (the HyCEAD method) allows for the capture and amplification of over 100 biomarkers simultaneously in a single reaction. The HyCEAD Ziplex system is ideal for measuring gene expression and other markers directly from Parsortix harvests and was used in the ovarian cancer pelvic mass triage test to achieve best in class accuracy (ROC-AUC) of 95.1%.
ANGLE's proprietary technologies can be combined to provide automated, sample-to-answer results in both centralised laboratory and point-of-use cartridge formats.
ANGLE has established formal collaborations with world-class cancer centres and major corporates such as Abbott, Philips and QIAGEN, and works closely with leading CTC translational research customers. These Key Opinion Leaders (KOLs) are working to identify applications with medical utility (clear benefit to patients), and to secure clinical data that demonstrates that utility in patient studies. The body of evidence as to the benefits of the Parsortix system is growing rapidly from our own clinical studies in metastatic breast cancer and ovarian cancer and also from KOLs with 23 peer-reviewed publications and numerous publicly available posters, available on our website.
This information is provided by RNS, the news service of the
Quick facts: ANGLE PLC
Market Cap: £107.13 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE